Clairvoyant Therapeutics announced that the first clinical trial participant in Finland enrolled in CLA-PSY-201 has received their first dose of the drug along with motivational enhancement therapy. CLA-PSY-201 is the company's placebo-controlled, randomized, multi-site phase 2b trial exploring psilocybin therapy as a treatment for alcohol use disorder.
The first CLA-PSY-201 trial site in Finland is overseen by principal investigator, Dr. Hannu Alho. Dr. Alho is a professor with the Finnish National Institute for Health and Welfare (THL) and chief doctor at Addiktum Oy, a Finnish company founded and owned by drug addiction treatment specialists and a research center for the study.
This milestone means the trial is now underway on two continents. "We are excited to randomize our first patient in Europe," stated Damian Kettlewell, CEO and co-founder, Clairvoyant. "Likewise, the Clairvoyant team is pleased that six clinical trial sites are recruiting patients in Canada and Europe. An accelerating number of dosing visits are scheduled in March and subsequent months. We look forward to opening eight additional sites in the coming quarter to expedite patient recruitment and have a clear line of sight on an interim data readout in Q3 2023 and full recruitment by Q4 2023. We appreciate the ongoing support of our experienced and well-resourced clinical, regulatory and financial team and partners."
Clairvoyant aims to be the first company to secure market authorization for psilocybin as a therapeutic product in Europe, the UK and Canada. The company remains on track to publish an interim data readout later this year.
Benzinga's Cannabis Capital Conference Is Back
The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference, returns to Miami for its 16th edition. This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out. Secure your tickets now. Prices will surge very soon.
Photo: Benzinga edit with photo by Pavel Danilyuk on pexels
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.